NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alesta Therapeutics

Alesta Therapeutics

Private
LeidenHealthcare & Life Scienceshttps://www.alestatherapeutics.com/

Last Round

Series A

Jan 8, 2025

Total Funding Raised

$67M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Alesta Therapeutics is a biotechnology company developing novel oral small molecule therapies for underserved rare diseases such as hypophosphatasia (HPP) and Charcot-Marie-Tooth (CMT).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

oral small moleculesrare disease therapeuticsorphan drugssmall molecule drugshypophosphatasiaHPPoral administrationCharcot-Marie-Tooth diseaseCMTdrug developmentinorganic pyrophosphatePPidrug licensingpreclinical biotechGCN2 inhibitorIntegrated Stress ResponsetRNA synthase mutations

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alesta Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Alesta Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Alesta Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 8, 2025

Alesta Therapeutics Investors

Notable investors and investment history

Alesta Therapeutics investors
InvestorRounds
Droia VenturesSeries A
Thuja CapitalSeries A
Frazier Life SciencesSeries A
RV InvestSeries A
RTW InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 105% MoM.

  • Apr 17, 2026

    Grew 17% QoQ, from 18 to 21 employees.

Alesta Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alesta Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alesta Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeiden
Employee Range21
Year Founded2021
Last FundingJan 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.